Adipose MSC Conversion to Autologous HS/PCs Without Co-Culture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods face challenges in converting adipose-derived mesenchymal stem cells (Ad MSCs) into functional hematopoietic stem/progenitor cells (HS/PCs) for clinical applications, lacking scalability, efficiency, and facing immunogenicity issues, while existing hematopoietic stem cell therapies like bone marrow transplantation suffer from complications such as graft-versus-host disease (GVHD).
Innovation Solution
A method and kit are developed to convert Ad MSCs into HS/PCs in vitro without exogenous genes or co-culture, achieving a conversion efficiency of over 10% and enhancing gene transfection efficiency 25-fold, along with protocols for differentiating HS/PCs into various blood cell types, using a unique culture medium and supplements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If Ad MSCs are converted to HS/PCs using conventional methods, then hematopoietic stem cell therapy can be provided, but the conversion efficiency is low and scalability is limited
Solution Approach 1:
The patent changes the chemical and physical parameters of the culture environment by using a defined medium containing specific growth factors (SCF, TPO, IL-3, IL-6, IL-11) and signaling molecules (Wnt3a, R-spondin 1, GSK3 inhibitors, BMP4) to achieve high conversion efficiency of Ad MSCs to HS/PCs, reaching over 10% conversion rate
Solution Approach 2:
The patent creates a simplified in vitro conversion system that replicates the complex in vivo bone marrow microenvironment through defined culture conditions, allowing scalable production of HS/PCs without requiring actual bone marrow tissue or complex co-culture systems
2Reliability
If bone marrow transplantation is used for hematopoietic stem cell therapy, then functional HS/PCs can be provided, but graft-versus-host disease and other complications occur
Solution Approach 1:
The patent extracts and isolates Ad MSCs from adipose tissue, which is abundant and easily accessible, then converts them to HS/PCs in a controlled in vitro system, eliminating the need for bone marrow transplantation and its associated risks of GVHD and infections
Solution Approach 2:
The patent uses autologous Ad MSCs from the patient's own adipose tissue to generate HS/PCs, making the therapy self-service and eliminating immune rejection risks and GVHD associated with allogeneic bone marrow transplantation
3Productivity
If Ad MSCs are converted to HS/PCs in vitro, then autologous HS/PCs can be produced, but the process lacks scalability for clinical use
Solution Approach 1:
The patent optimizes culture parameters including medium composition (defined medium with specific growth factors), temperature (37°C), CO2 concentration (5%), and passage number to achieve consistent high conversion efficiency and cell viability, enabling scalable clinical production
Solution Approach 2:
The patent creates a simplified, standardized in vitro conversion protocol that can be replicated in different laboratories and scaled up for clinical use, replacing complex in vivo procedures with a manageable in vitro system that maintains high conversion efficiency
4Manufacturing precision
If conventional Ad MSC conversion methods are used, then HS/PCs can be generated, but gene transfection efficiency is low
Solution Approach 1:
The patent changes the cellular state and membrane properties of Ad MSCs during the conversion process by using specific growth factors and signaling molecules, making the cells more receptive to gene transfection and achieving over 25-fold enhanced transfection efficiency
Data Source
AI summary
A method of producing hematopoietic stem/progenitor cells (HS/PCs) and blood cells from adipose derived mesenchymal stem cells (Ad MSCs). The method comprises obtaining biological cells of a subject; expanding the biological cells; obtaining a pure Ad MSCs cell line from the expanded biological cells; converting the pure Ad MSCs cell line into HS/PCs in vitro; expanding the converted HS/PCs in vitro; and obtaining the expanded HS/PCs.